Mr. Chair, perhaps I'll take a moment to explain how we worked throughout the pandemic with provinces and territories on vaccine distribution.
We work as an intermediary between, obviously, the provinces and territories and then down to the local level and the vaccine companies. Some provinces and territories have fairly robust logistics systems and capacity. They have warehousing capacity that they use, and in some cases can take delivery directly to other jurisdictions. In other cases, we hold it centrally and then distribute it to the provinces and territories as they require it.
We've put a lot of effort, over the last two-plus years, into having very strong relationships with the logistics teams in each of the jurisdictions, to have a good line of sight on exactly what their needs are. It has evolved over time, and I think the audit has highlighted that in the early days a lot of effort had to go into building the systems. My colleague Luc Gagnon has explained that we are now working on the technological platforms and evolving them so that we can do that more efficiently.
I think, in the context of the ability to use doses, one of the things we are very keen to work on with the provinces and territories is real-time data sharing, so that we can reallocate doses quickly if there are jurisdictions that cannot use them. We have done that on many occasions. When we've polled and canvassed jurisdictions to ask them if they have additional need, we've reallocated between jurisdictions, working collaboratively with provinces and territories.
One point I would make is that when you think about the full vaccine rollout, thousands of points of distribution and administration occurred across Canada. That was one of the challenges we faced. We're continuing to learn from the lessons on how we can be better prepared for the next pandemic in terms of being able to have data right down to the local level.
Thank you.